ALK and anaplastic large cell lymphoma: The safety and efficacy of BV as monotherapy (1.8 mg/kg, once every 3 weeks for up to 16 cycles) were evaluated in a Phase II study in 58 patients (median age 52 years) with R/R ALCL, mostly ALK‐negative [155].